Adverum Biotechnologies to Present at Upcoming Investor Conferences

February 21, 2017

MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at two upcoming investor conferences:

  • Cowen and Company 37th Annual Health Care Conference
    Date: Monday, March 6, 2017
    Time: 2:40pm ET
    Location: Boston, MA

  • 29th Annual ROTH Conference
    Date: Monday, March 13, 2017
    Time: 7:30am PT
    Location: Laguna Niguel, CA

The audio portions of the corporate presentations will be accessible live through the investors’ section of the Company’s website at A replay will be available for 14 days following the presentations.

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE).  Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit

Contact for Adverum:
Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.

Jill Steier
Senior Vice President
The Trout Group LLC

Primary Logo


Adverum Biotechnologies, Inc.